| 21.11 0.42 (2.03%) | 05-16 13:34 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 26.18 | 1-year : | 30.58 |
| Resists | First : | 22.42 | Second : | 26.18 |
| Pivot price | 20.36 |
|||
| Supports | First : | 18.42 | Second : | 15.96 |
| MAs | MA(5) : | 20.53 |
MA(20) : | 20.29 |
| MA(100) : | 29.04  |
MA(250) : | 27.82 |
|
| MACD | MACD : | 0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 66.4 |
D(3) : | 59.8 |
| RSI | RSI(14): 54 |
|||
| 52-week | High : | 61.06 | Low : | 1.39 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ TECX ] has closed below upper band by 24.6%. Bollinger Bands are 76.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 26 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 21.34 - 21.46 | 21.46 - 21.57 |
| Low: | 19.22 - 19.37 | 19.37 - 19.5 |
| Close: | 20.47 - 20.69 | 20.69 - 20.89 |
Tectonic Therapeutic, Inc., a clinical stage biotechnology company focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G-protein coupled receptors(GPCRs). It offers GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's pipeline products include RXFP1 agonist, which is in ongoing phase 1a and 1b for the indication of heart failure with preserved ejection fraction; GPCR antagonist for indication of hereditary hemorrhagic telangiectasia; bi-functional GPCR modulator for indication of fibrosis; and GPCR modulators. Tectonic Therapeutic, Inc. is based in Watertown, Massachusetts.
Tue, 13 May 2025
Wall Street Analysts See a 258.52% Upside in Tectonic Therapeutic, Inc. (TECX): Can the Stock Really Move This High? - Nasdaq
Thu, 08 May 2025
Tectonic Therapeutic Inc reports results for the quarter ended March 31 - Earnings Summary - TradingView
Thu, 08 May 2025
Tectonic Therapeutic Announces First Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewswire
Wed, 07 May 2025
Tectonic Therapeutic To Present on May 15th, 2025 at the Bank of America Securities Health Care Conference - Stock Titan
Wed, 23 Apr 2025
Tectonic Therapeutic: A Buy On Massive Opportunity Of TX45 In PH HFpEF - Seeking Alpha
Mon, 21 Apr 2025
Mizuho Initiates Coverage of Tectonic Therapeutic (TECX) with Outperform Recommendation - Nasdaq
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 19 (M) |
| Shares Float | 10 (M) |
| Held by Insiders | 38.2 (%) |
| Held by Institutions | 43.9 (%) |
| Shares Short | 1,510 (K) |
| Shares Short P.Month | 882 (K) |
| EPS | -6.83 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 9.47 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -37.8 % |
| Return on Equity (ttm) | -84.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -3.02 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -59 (M) |
| Levered Free Cash Flow | -65 (M) |
| PE Ratio | -3.11 |
| PEG Ratio | 0 |
| Price to Book value | 2.23 |
| Price to Sales | 0 |
| Price to Cash Flow | -6.7 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|